Marker Highlights Expanded Manufacturing Support For MT-601

Marker Therapeutics said its lead cell-therapy program, MT-601 (neldaleucel), will gain expanded manufacturing capabilities through the formation of Kincellis Advanced Therapies, a U.S. cell-therapy contract development and manufacturing organization. The development could support MT-601's production capacity and clinical advancement, though no financial terms, capacity figures, or development timelines were disclosed.